Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 12/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | USP19 | O94966 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283059 | 0.97 | HCRTR1 (0.40) | HCRTR1HCRTR2CHEK2USP19 | |
| SCHEMBL13705474 | 0.96 | HCRTR1 (0.38) | HCRTR1HCRTR2CHEK2CHRM3 | |
| SCHEMBL13819265 | 0.96 | HCRTR1 (0.38) | HCRTR1HCRTR2CHEK2CHRM3 | |
| SCHEMBL13705452 | 0.95 | HCRTR1 (0.38) | HCRTR1HCRTR2CHRM3USP19 | |
| SCHEMBL13705466 | 0.94 | HCRTR1 (0.41) | HCRTR1HCRTR2CHEK2CHRM3USP19 | |
| SCHEMBL13705419 | 0.93 | HCRTR1 (0.40) | HCRTR1HCRTR2CHEK2 | |
| SCHEMBL13705411 | 0.93 | HCRTR1 (0.43) | HCRTR1HCRTR2CHEK2CHRM3USP19 | |
| SCHEMBL8126947 | 0.93 | HCRTR1 (0.40) | HCRTR1HCRTR2CHEK2 | |
| SCHEMBL8124697 | 0.93 | HCRTR1 (0.43) | HCRTR1HCRTR2CHEK2CHRM3USP19 | |
| SCHEMBL4292457 | 0.92 | HCRTR1 (0.39) | HCRTR1HCRTR2CHEK2CHRM3USP19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR1 3147/4885HCRTR2 3136/4885CHEK2 3289/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR1 3147/4885HCRTR2 3136/4885CHEK2 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.